Michael P DiGiovanna, MD, PhD

Associate Professor of Medicine (Medical Oncology) and of Pharmacology

Research Interests

Breast Neoplasms

Research Organizations

Cancer Center, Yale: Signal Transduction

Medical Oncology

Signal Transduction

Research Summary

We study signal transduction by growth factor receptor tyrosine kinases, focusing on the EGFR/HER2/ErbB family, including the impact of signaling by these receptors on clinical outcomes and response to targeted therapies for cancer, and their potential as therapeutic targets in novel combination therapies. A major focus in our laboratory has been the interaction of HER2 signaling with estrogen receptor (ER) signaling in breast cancer, and more recently with IGF-I receptor signaling, and the effects of inhibitors of these receptors in combination targeted therapies. We have also found that in breast cancer patients, tumors harboring activated HER2 have adverse prognosis, and these tumors have co-overexpression of EGFR. We continue to study how signaling by these receptors impacts responses to different types of therapies and explore targeting these receptors in combination with other novel targeted therapeutics.

Extensive Research Description

We study signal transduction by growth factor receptor tyrosine kinases, focusing on the EGFR/HER2/ErbB family, including the impact of signaling by these receptors on clinical outcomes and response to targeted therapies for cancer, and their potential as therapeutic targets in novel combination therapies. A major focus in our laboratory has been the interaction of HER2 signaling with estrogen receptor (ER) signaling in breast cancer, and more recently with IGF-I receptor signaling, and the effects of inhibitors of these receptors in combination targeted therapies. We have also found that in breast cancer patients, tumors harboring activated HER2 have adverse prognosis, and these tumors have co-overexpression of EGFR. We continue to study how signaling by these receptors impacts responses to different types of therapies and explore targeting these receptors in combination with other novel targeted therapeutics.Therapeutic implications of interactions of IGF-I receptor with HER2 and estrogen receptor

Selected Publications

Edit this profile

Contact Info

Michael P DiGiovanna, MD, PhD
Patient Care Locations
Yale Medical OncologySmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 1st Floor

New Haven, CT 06511
Yale Breast Cancer ProgramSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 4th Floor

New Haven, CT 06511
Yale-New Haven Hospital
20 York Street

New Haven, CT 06510
Yale Physicians Building
800 Howard Avenue

New Haven, CT 06519
Yale Physicians Building
800 Howard Avenue

New Haven, CT 06519
Yale Physicians Building
800 Howard Avenue

New Haven, CT 06519
Yale Physicians Building
800 Howard Avenue

New Haven, CT 06519
Lab Location
300 George Street, Ste 7th Floor
New Haven, CT 06511
Office Locations
300 George Street, Ste Suite 120
New Haven, CT 06511
testSheffield-Sterling-Strathcona
1 Prospect Street, Wing test

New Haven, CT 06511
Sheffield-Sterling-Strathcona
1 Prospect Street

New Haven, CT 06511
Mailing Address
Yale Cancer CenterPO Box 208032
300 George Street

New Haven, CT 06520-8032